Sort
39,280 grants matching “leukemia”
MPN-inducing mutations as biomarkers of synthetic lethality
$427,660Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2020 · CA
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
$427,572Joseph P Balthasar · State University Of New York At Buffalo · R01 · FY2025 · CA
Development and Function of Natural Autoreactive B Cells
$427,569Kyoko Hayakawa · Research Inst Of Fox Chase Can Ctr · R01 · FY2012 · AI
Development and Function of Natural Autoreactive B Cells
$427,569Kyoko Hayakawa · Research Inst Of Fox Chase Can Ctr · R01 · FY2011 · AI
Mechanistic dissection of HP1 mediated heterochromatin
$427,560Geeta Narlikar · University Of California, San Francisco · R01 · FY2015 · GM
miRNA Profiling in Fixed Cancer Samples
$427,526Anna Schwarzbach · Ambion Diagnostics, Inc. · R44 · FY2009 · CA
Synthetic Lethal Targeting of p53 in Myelodysplasia
$427,500A Thomas Look · Dana-Farber Cancer Inst · R01 · FY2011 · HL
Leukemogenic Slug Pathway in Hematopoietic Cell Survival
$427,500Dana-Farber Cancer Institute · R01 · FY2004 · CA
Synthetic Lethal Targeting of p53 in Myelodysplasia
$427,500A Thomas Look · Dana-Farber Cancer Inst · R01 · FY2009 · HL
Antiretroviral Activity of TRIM5alpha
$427,500Dana-Farber Cancer Institute · R01 · FY2005 · AI
Leukemogenic Slug Pathway in Hematopoietic Cell Survival
$427,500Dana-Farber Cancer Institute · R01 · FY2005 · CA
Molecular Analysis of Normal and Thalassemic DNA
$427,500Stuart H Orkin · Boston Children'S Hospital · R01 · FY2009 · HL
Genetic Heterogeneity and Protein Function in DBA
$427,500Dana-Farber Cancer Institute · R01 · FY2003 · HL
Synthetic Lethal Targeting of p53 in Myelodysplasia
$427,500A Thomas Look · Dana-Farber Cancer Inst · R01 · FY2010 · HL
Synthetic Lethal Targeting of p53 in Myelodysplasia
$427,500A Thomas Look · Dana-Farber Cancer Inst · R01 · FY2008 · HL
HIV-1 Preintegration Trafficking and Nuclear Localization
$427,500Alan N. Engelman · Dana-Farber Cancer Inst · R01 · FY2007 · AI
Synthetic Lethal Targeting of p53 in Myelodysplasia
$427,500A Thomas Look · Dana-Farber Cancer Inst · R01 · FY2007 · HL
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL
$427,457Brian C Betts · University Of Minnesota · R01 · FY2018 · HL
Biodefense Project
$427,444Steven Simon · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA
Cellular factors in gammaretrovirus replication
$427,389John A T Young · Salk Institute For Biological Studies · R01 · FY2011 · AI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma
$427,373Richard Goff James · Seattle Children'S Hospital · R01 · FY2018 · CA
Hematopoietic Stem Cell Transplant for Immunodeficiency with MDS
$427,245Dennis Hickstein · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Selective Instructions for Memory T Cells
$427,230Hilde Cheroutre · La Jolla Institute For Immunology · R01 · FY2013 · AI
Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma
$427,202Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2023 · NS
LY-1 B CELLS: DEVELOPMENTAL ORIGINS AND V GENE BIASES
$427,182Institute For Cancer Research · R01 · FY2001 · AI